高级检索
当前位置: 首页 > 详情页

Withaferin A downregulates COX-2/NF-kappa B signaling and modulates MMP-2/9 in experimental endometriosis

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]WuHan Univ, Tongren Hosp, Wuhan Hosp 3, Dept Obstet & Gynecol, Wuhan 430060, Peoples R China [2]Hubei Prov Hosp Integrated Chinese & Western Med, Dept Obstet & Gynecol, Wuhan 430015, Peoples R China
出处:
ISSN:

关键词: Endometriosis Inflammation Matrix metalloproteinases Nuclear factor-kappa B signaling Withaferin A

摘要:
Purpose: To study the effect of withaferin A on an experimentally-induced endometriosis (EM) model. Methods: Female Sprague-Dawley rats were induced EM by implantation of autologous endometrium. Rats in the treatment group were administered withaferin A orally for 30 days. A separate group of rats that was administered gestrinone (G TN) served as positive control. Results: Withaferin A treatment reduced the spherical volume of the ecto-uterine tissue was following five weeks after implantation. Histological analysis revealed regression of the lesions and restoration of normal architecture. Withaferin A effectively down-regulated the expressions and activities of matrix metalloproteinases (MMPs) 2 and 9 in the ectopic endometrium. The activities of MMPs-2 and 9 significantly (p<0.05) decreased from 1.79- and 1.65-fold to 1.08- and 1.1-fold, respectively. The EM-induced up-regulation of NF-kappa B/COX-2 signaling was down-regulated by withaferin A. The levels of Cox-2 decreased significantly (p < 0.05) from 198 % in EM control rats to 122.7 % in 150 mg withaferin A treated EM-induced rats. The increased levels of major inflammatory mediators nitric oxide (NO), TNF-alpha, Interleukins (IL) - IL-1 beta and IL-6, markedly (p < 0.05) were reduced by withaferin A treatment, when compared to EM control group. Conclusion: Withaferin A effectively suppresses the proliferation of lesions and modulates the immune responses-associated expressions of COX-2, NF-kappa B and matrix metalloproteinases (MMPs), viz, MMP-2 and MMP-9

语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 4 区 医学
小类 | 4 区 药学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 药学
JCR分区:
出版当年[2019]版:
Q4 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q4 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]WuHan Univ, Tongren Hosp, Wuhan Hosp 3, Dept Obstet & Gynecol, Wuhan 430060, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21169 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)